Skip to main
TEM

TEM Stock Forecast & Price Target

TEM Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 64%
Buy 9%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

Tempus AI Inc. demonstrated significant financial growth, with total revenue increasing by 84.7% year-over-year, driven primarily by a remarkable 117.2% growth in Genomics revenue, which reached $252.9 million. The company is poised to benefit from higher average selling prices (ASPs) due to an anticipated shift towards more premium offerings, including the xF liquid biopsy assay and the xT CDx test, which are expected to enhance profitability. Additionally, the continued expansion of oncology testing volumes and the potential for securing reimbursement in the minimal residual disease segment indicate a robust growth trajectory for Tempus AI's business model.

Bears say

Tempus AI Inc. has experienced a decline in gross margins within the Data & Other segment, decreasing from 76.8% in Q3 of the previous year to 69.7% in Q3 of the current reporting period. Additionally, the company faces significant financial risks, including lower-than-anticipated sales growth due to competitive pressures and regulatory hurdles, as well as ongoing substantial losses and debt that may hinder its ability to achieve sustainable profitability. Despite a revenue increase to $334.2 million, the adjusted EBITDA was notably below both internal estimates and consensus expectations, highlighting potential challenges in operational efficiency and revenue generation moving forward.

TEM has been analyzed by 11 analysts, with a consensus rating of Buy. 64% of analysts recommend a Strong Buy, 9% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tempus AI Inc (TEM) Forecast

Analysts have given TEM a Buy based on their latest research and market trends.

According to 11 analysts, TEM has a Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $82.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $82.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tempus AI Inc (TEM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.